Independence in Pharmacy Review: Why Separation of Supply and Review Matters

Introduction: The Foundation of Objective Clinical Review

In nearly a decade of working with Australian insurers, one principle consistently separates best-practice pharmacy programmes from those that fall short: the entity recommending or conducting a clinical medication review must never be the same entity that profits from medication supply.

This isn't just a preference or a compliance technicality. It's a structural safeguard for objectivity, and it has profound implications for clinical outcomes, insurer risk management, and injured worker safety. Yet across the insurance pharmacy landscape, this principle remains poorly understood-and inconsistently applied. This article explores why independence matters, how conflicts of interest operate in practice, and why the separation of supply and review functions is fundamental to best-practice pharmacy management.

The Conflict of Interest: How Financial Incentives Affect Clinical Judgment

What Is a Conflict of Interest in Pharmacy Review?

A conflict of interest arises when an individual or organisation has a financial incentive (profit or revenue) that could influence their professional judgment. In pharmacy review, the conflict is straightforward:

This isn't to suggest dishonesty. Research in behavioural economics and organisational psychology consistently shows that unconscious bias operates even among well-intentioned professionals. When financial incentives are present, they influence decision-making in subtle ways-ways the decision-maker may not even recognise.

How This Plays Out in Practice

Consider a medication supply company that dispenses medications to injured workers on insurance claims. Over time, they accumulate detailed medication history data for each patient. This data is valuable: it shows which medications the patient is taking, how often they're refilled, which doctors are prescribing them, and which pharmacies are involved. From this vantage point, the supply company then recommends when a medication review should be conducted.

The problem is subtle but significant: the supply company profits from ongoing dispensing. Every medication that continues to be supplied generates revenue. While they may genuinely want to identify high-risk prescribing, their revenue model creates an incentive to recommend reviews only when risks are severe enough to clearly justify the expense-not when early intervention might prevent risk from developing in the first place. Early, proactive review might reduce medication supply volumes and revenue.

In academic and regulatory literature, this dynamic is well-documented. Organisations with vertical integration-where supply and clinical functions sit under the same roof-tend to make decisions that optimise for profit, not clinical outcomes, even when those decisions contradict explicit intentions.

Why Independence Produces Better Clinical Outcomes

Objectivity in Risk Identification

An independent clinical pharmacy team-one with no involvement in medication supply-can assess medication risk purely on clinical grounds. They can ask: "Is this prescribing pattern optimal? Are there safer alternatives? Is there evidence of drug interactions, overmedication, or dependency risk?" without any financial incentive pulling toward or away from a particular answer.

This objectivity is not just theoretically superior-it produces measurably better outcomes:

• Earlier intervention: Independent pharmacists can recommend review at the earliest signs of risk, not only when risk is severe. This allows proactive management rather than reactive crisis intervention.
• Broader risk capture: Without revenue incentives linked to supply, independent pharmacists can identify risks that don't directly threaten patient safety but do represent inefficiency, overtreatment, or misalignment with best practice.
• Trust with treating doctors: Treating practitioners are more likely to engage with pharmacy recommendations from an organisation with no financial stake in medication supply. This increases the likelihood that recommendations are actually implemented.

Clinical Credibility and Professional Standards

Professional pharmacy standards globally emphasise the importance of independence in clinical practice. Pharmacists' professional code of ethics requires them to prioritise patient welfare over commercial interests. When a pharmacist works for an organisation with a financial stake in medication supply, that code becomes harder to follow-not because the pharmacist is unprofessional, but because the organisation's structure creates an inherent tension.

In contrast, an independent pharmacy organisation can claim-and demonstrate-that all recommendations flow from clinical judgment alone.

How Integrated Risk Stratification Plus Independence Creates the Gold Standard

The IMM Model: Technology and Independence Working Together

The most effective approach to pharmacy risk management in insurance combines two elements: integrated risk stratification technology within the insurer's team, and independent pharmacists tasked with implementing change.

Here's how this works in practice:

Step 1: Intelligent Risk Stratification (Embedded in Insurer's Team)

Risk stratification technology-powered by AI-driven rules engines-analyses medication documents (pharmacy receipts, dispense histories, Webster packs, independent medical exam reports) in real time and classifies medication risk based on Therapeutic Goods Administration (TGA) guidelines, Pharmaceutical Benefits Scheme (PBS) compliance, and opioid prescribing standards. This turns what would be a 2-4 hour manual review into a 2-minute automated assessment.

Because this technology sits within the insurer's claims team, it serves the insurer's interests directly: identifying genuine risks that affect the claim, cost, and injured worker safety. There is no commercial incentive tied to the output-only the desire for accurate risk classification.

Step 2: Independent Clinical Pharmacists Implement Tailored Medication Management Strategies

Once risk is identified, independent clinical pharmacists step in. These pharmacists have no involvement in medication supply. Their role is to translate risk stratification into real clinical action through:

• Detailed clinical assessment: Understanding the context behind high-risk medications-why they were prescribed, whether there are safer alternatives, and what patient-specific factors apply.
• Tailored medication management strategies: Developing specific, actionable plans to reduce risk-which might include dose optimisation, deprescribing, switching to safer alternatives, or more frequent monitoring.
• Direct communication with prescribers: Independent pharmacists communicate findings and recommendations directly to treating doctors, both verbally and in writing. This is critical-a recommendation that stays in a report has no clinical impact. A recommendation discussed directly with the prescriber stands a far better chance of being implemented.
• Insurer support: Detailed written reports provide insurers with evidence-based justification for claim management decisions and help structure ongoing medication monitoring.

Because these pharmacists are independent-not employed by the insurer, not involved in supply-they can make recommendations based purely on clinical evidence and best practice, even if those recommendations are inconvenient for the insurer or reduce medication volumes.

Why This Model Succeeds Where Others Fall Short

This dual-layer approach (technology + independence) outperforms single-function models because it combines:

Component	Advantage
Intelligent Risk Identification	Catches medication risks systematically and quickly; removes subjectivity from the question "does this claim need review?"
Independent Clinical Judgment	Ensures recommendations flow from clinical evidence, not financial incentives; increases prescriber buy-in and treatment adherence
Direct Prescriber Communication	Converts recommendations into real clinical change; gives treating doctors the clinical context to adjust prescribing in real time
Insurer Access to SafeScript/QScript	Approved pharmacists can monitor high-risk prescribing in real time-not retrospectively from invoices weeks later-enabling early intervention before harm occurs

The contrast with integrated supply-and-review models is stark: when one organisation handles both, it optimises for revenue and efficiency within its own business. When technology and pharmacists are separate-aligned with the insurer's outcomes, not a commercial entity's profit-they optimise for genuine risk reduction and clinical safety.

Regulatory Expectation: Independence as Best Practice

What Do Regulators Expect?

Australia's leading workers compensation regulator, the State Insurance Regulatory Authority (SIRA) in New South Wales, provides clear guidance in its Medication Management in the NSW Personal Injury Schemes: Better Practice Guide. Whilst SIRA does not explicitly mandate the separation of supply and review functions, the regulatory expectation is unmistakable:

The emphasis on "independent assessment" reflects a foundational regulatory principle: clinical reviews must be objective and free from conflicting interests. SIRA expects insurers to seek medication reviews from organisations that can genuinely claim independence-where the reviewing pharmacist has no financial interest in the outcome.

Similar principles appear across state and territory frameworks. Regulators understand that objective review protects injured workers, supports treating doctors, and reduces long-term medication-related harms.

The Practical Impact on Claims Management

What This Means for Insurance Claims Teams

In practical terms, independence in pharmacy review translates into:

• Earlier risk identification: Independent pharmacists can recommend intervention as soon as risk emerges-not only when it reaches crisis levels.
• More complete risk picture: Without revenue incentives, independent assessment captures risks that affect claim trajectory but might not impact supply volume.
• Stronger prescriber relationships: Treating doctors are more likely to engage with pharmacy recommendations from an independent source. They know the pharmacist has no commercial interest in the outcome.
• Better compliance with clinical recommendations: When recommendations come from independent experts and are communicated directly by those experts to prescribers, implementation rates are higher.
• Measurable cost control: Early intervention and proactive deprescribing, driven by independent clinical judgment, reduce long-term medication costs more effectively than retrospective review alone.

Addressing Common Misconceptions

Isn't Supply Data Useful for Risk Identification?

Yes, it is-but not as the sole source of information, and not when the data controller has a commercial interest in medication supply. Supply data can be input to risk stratification (and should be), but the decision about whether and when to intervene must come from an independent clinical assessment. Technology embedded in the insurer's claims team can analyse supply data objectively; an organisation that profits from supply cannot.

Don't Independent Pharmacists Also Cost More?

Independent clinical pharmacy services are an investment in early intervention and risk reduction. While they have an upfront cost, they reduce long-term medication costs, hospital admissions, and claim duration through proactive medication optimisation. Integrated supply-and-review models may appear cheaper upfront but often miss early intervention opportunities and optimise for supply volume rather than risk reduction.

Aren't All Pharmacists Professional and Unbiased?

Individual pharmacists are professional and well-intentioned. However, research in behavioural economics and organisational psychology shows that financial incentives influence decision-making at an unconscious level, even among ethical professionals. Independence removes this influence. It's not about questioning individual integrity; it's about recognising how organisational structure affects judgment.

Conclusion: Independence as a Strategic Investment

In over a decade of working with Australian insurers, the insurers that consistently achieve the best medication management outcomes-lower costs, fewer complications, better compliance with clinical recommendations, shorter claim duration-are those that separate medication supply from clinical review. They invest in independent pharmacy expertise, use technology to stratify risk within their own teams, and rely on independent pharmacists to drive clinical change.

This approach works because it aligns all incentives with genuine risk reduction and clinical best practice. There are no hidden tensions between commercial interest and clinical judgment. Recommendations flow from evidence, not revenue.

Independence matters because it produces better outcomes. It's not just a compliance principle or an ethical ideal-it's a structural requirement for objective clinical decision-making in medication management. As the insurance industry evolves, this principle will only become more important.